- Differential Diagnosis
Drug Information for ELAPRASE™ (idursulfase) Solution for intravenous infusionInitial U.S. Approval: 2006 (Shire US Manufacturing Inc.): 16. HOW SUPPLIED/STORAGE AND HANDLING
- WARNING: Risk of Anaphylaxis
- 1. INDICATIONS AND USAGE
- 2. DOSAGE AND ADMINISTRATION
- 3. DOSAGE FORMS AND STRENGTHS
- 4. CONTRAINDICATIONS
- 6. ADVERSE REACTIONS
- 7. DRUG INTERACTIONS
- 10. OVERDOSAGE
- 11. DESCRIPTION
- 14. CLINICAL STUDIES
- 16. HOW SUPPLIED/STORAGE AND HANDLING
- 17. PATIENT COUNSELING INFORMATION
- PRINCIPAL DISPLAY PANEL - 6 mg/3 mL Vial Carton
- External Links Related to ELAPRASE™ (idursulfase) Solution for intravenous infusionInitial U.S. Approval: 2006 (Shire US Manufacturing Inc.)
ELAPRASE is a sterile, aqueous, clear to slightly opalescent, colorless solution supplied in a 5 mL Type I glass vial. The vials are closed with a butyl rubber stopper with fluororesin coating and an aluminum overseal with a blue flip-off plastic cap.
Store ELAPRASE vials under refrigeration at 2°C to 8°C (36°F to 46°F), and protect from light. Do not freeze or shake. Do not use ELAPRASE after the expiration date on the vial.
This product contains no preservatives. The diluted solution should be used immediately. If immediate use is not possible, the diluted solution can be stored refrigerated at 2°C to 8°C (36°F to 46°F) for up to 48 hours, or must be administered within 8 hours if held at room temperature.
- Drug Information Provided by National Library of Medicine (NLM).